EHA 2019: Venetoclax plus obinutuzumab improves PFS and MRD negativity in patients with previously untreated CLL and comorbidities

Kirsten Fischer | EHA 2019 | KESÄKUU 17, 2019

Asiantuntija: Kirsten Fischer

Fixed-duration VenG induced deep, high and long lasting MRD-negativity rates (with a low rate of conversion to MRD-positive status 1 year after treatment) in previously untreated pts with CLL and comorbidities, translating into improved PFS.